Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer

ABSTRACT IMscin001 is a two‐part dose‐finding (Phase Ib) and ‐confirmation (Phase III) study to evaluate atezolizumab pharmacokinetics of subcutaneous (SC) compared with intravenous (IV) administration in patients with locally advanced or metastatic non‐small cell lung cancer (NSCLC). The objectives...

Descripció completa

Dades bibliogràfiques

Autors principals:	Phyllis Chan, Stephanie N. Liu, Nathalie Gosselin, Zacharie Sauve, Mathilde Marchand, Alyse Lin, Luis Herraez‐Baranda, James Zanghi, Esther Shearer‐Kang, Xiaoyan Liu, Benjamin Wu, Pascal Chanu
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2025-04-01
Col·lecció:	CPT: Pharmacometrics & Systems Pharmacology
Accés en línia:	https://doi.org/10.1002/psp4.13310
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!